US.BIIB · Biogen

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.4,
      "details": {
        "atrPct": 2.7241892827530076,
        "turnoverUsdM": 173.31462973559002,
        "liquidityPoints": 0.4,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.8,
    "stopLevels": {
      "symbol": "US.BIIB",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 202.6714,
      "strength_details": {
        "ma_score": 2,
        "atr_score": 2,
        "rsi_score": 3,
        "macd_score": 3,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1.7,
      "stop_loss_percent": 5.4,
      "take_profit_price": 233.6197,
      "target_multiplier": 2.2,
      "technical_strength": 2.25,
      "take_profit_percent": 9
    },
    "positionPoints": 1.4,
    "stopLossPoints": 1.8,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Health Care",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.6518675954309592,
    "stopLossPercent": 5.448378565506015,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 67.2,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 60.2,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 7
  },
  "market": {
    "ma20": 207.8575,
    "ma50": 204.8222,
    "close": 214.35,
    "prevClose": 221.56,
    "avgVolume20": 957603,
    "volumeRatio": 0.84,
    "changePercent": -3.25
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 7,
    "details": {
      "ret_5d": 0.01756477652811661,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 7,
      "vcp_bonus": 0,
      "vol_ratio": 0.834615702223415,
      "ret_points": 4,
      "vol_points": 0,
      "range_ratio": 1.1569002639601502,
      "volat_points": 0,
      "day_range_pct": 0.03312334811647544,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 3,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 67.2,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 2.2,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 44,
        "contribution": 2.2
      },
      {
        "raw": 10.8,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 54,
        "contribution": 10.8
      },
      {
        "raw": 6.8,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 45.33,
        "contribution": 6.8
      },
      {
        "raw": 2,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 10,
        "contribution": 2
      },
      {
        "raw": 7,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 70,
        "contribution": 7
      },
      {
        "raw": 25.4,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 84.67,
        "contribution": 25.4
      },
      {
        "raw": 6,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 60,
        "contribution": 6
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "觀望",
    "result": 60.2,
    "details": [
      "基本面分析總分: 2.2/5分",
      "資金流分析總分: 10.8/20分",
      "市場環境分析總分: 6.8/15分",
      "催化劑分析: 2/20分",
      "風險管理總分: 7/10分",
      "技術信號分析總分: 25.4/30分",
      "情緒分析: 6/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 2,
      "基本面": 2.2,
      "資金流": 10.8,
      "市場環境": 6.8,
      "情緒分析": 6,
      "技術信號": 25.4,
      "風險管理": 7
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 2,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "catalystCount": 0
            }
          },
          "catalystPoints": 2
        }
      },
      "基本面": {
        "max": 5,
        "grade": "較差",
        "items": {
          "pbPoints": 0.5,
          "pePoints": 0.2,
          "epsPoints": 0,
          "roePoints": 0,
          "debtPoints": 0.5,
          "marginPoints": 0,
          "turnoverUsdM": 173.31462973559002,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 0.8,
          "mfiPoints": 2.4,
          "obvPoints": 1.6,
          "vwapPoints": 4,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.BIIB",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 3,
            "details": {
              "qqq": {
                "ma20": 707.7280003500002,
                "ma50": 713.0466018399998,
                "name": "QQQ",
                "close": 710.92999,
                "points": 1
              },
              "spy": {
                "ma20": 760.98750315,
                "ma50": 750.9438048,
                "name": "SPY",
                "close": 762.59998,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.7241892827530076,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 3
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "一般",
        "items": {
          "sentiment": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 8,
              "negativeHits": 0,
              "positiveHits": 4,
              "sentimentScoreRaw": 1.2
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141237366,
                "url": "https://finnhub.io/api/news?id=7520059c1e635c3a1db5a71abc23c482a4e538243e4691dbd434400fd30c87ea",
                "image": "https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp",
                "source": "ChartMill",
                "related": "BIIB",
                "summary": "Biogen (BIIB) flashes a perfect technical rating and strong breakout setup, with a proposed entry at $215.61 and defined stop.",
                "category": "company",
                "datetime": 1786965108,
                "headline": "Biogen (NASDAQ:BIIB) Shows Strong Technical Breakout Setup With Perfect Trend Rating"
              },
              {
                "id": 141154813,
                "url": "https://finnhub.io/api/news?id=d1a25cbee937c8d8a8e9cf11267b548cc0e980b847cbb4c2a4d7e9ec0901a396",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Growth portfolio revenue surpassed legacy MS franchise for second consecutive quarter.",
                "category": "company",
                "datetime": 1786147363,
                "headline": "Biogen (BIIB) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141087814,
                "url": "https://finnhub.io/api/news?id=79c85db271e7d964af8764123ce35f25b0d723af71c3b68905827751789ec757",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biotech company Biogen (NASDAQ:BIIB) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 3.4% year on year to $2.74 billion. Its non-GAAP profit of $3.60 per share was 75.8% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785599277,
                "headline": "BIIB Q2 Deep Dive: Portfolio Expansion and Pipeline Readouts Drive Upbeat Outlook"
              },
              {
                "id": 141063522,
                "url": "https://finnhub.io/api/news?id=34ff54a8cc17094f79ad56c7f69dd8888cad6a9c08f1569e4bc5d2b14f34c7e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Inc. has released its second-quarter 2026 results, reporting revenue of US$2.74 billion versus US$2.65 billion a year earlier, while net income dropped to US$97.5 million and diluted EPS from continuing operations fell to US$0.66 from US$4.33. Despite modest revenue growth for both the quarter and first half of 2026, Biogen’s profitability compressed sharply, with six‑month net income falling to US$417.0 million from US$875.3 million, highlighting a widening gap between sales...",
                "category": "company",
                "datetime": 1785391731,
                "headline": "Biogen (BIIB) Is Up 5.8% After Earnings Compression Amid Revenue Growth – Is Profitability Peaking?"
              },
              {
                "id": 141058596,
                "url": "https://finnhub.io/api/news?id=bcb4bce5f67ee0ae88d03f86cff4bcf7e28aac5f04e8b3f4a884222a40c71393",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Inc (BIIB) reports a 3% revenue increase, driven by a robust growth portfolio and strategic acquisitions, despite facing market challenges.",
                "category": "company",
                "datetime": 1785359014,
                "headline": "Biogen Inc (BIIB) Q2 2026 Earnings Call Highlights: Strong Growth in Core Pharmaceuticals and ..."
              },
              {
                "id": 141056937,
                "url": "https://finnhub.io/api/news?id=0873deb1760e30eec26325069b9aef7c10238b0e43c98c712ebff7fe9c252aae",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Biogen Inc. (BIIB) Q2 2026 Earnings Call July 29, 2026 8:30 AM EDTCompany ParticipantsTim Power - Head of Investor RelationsChristopher Viehbacher -...",
                "category": "company",
                "datetime": 1785340401,
                "headline": "Biogen Inc. (BIIB) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141054426,
                "url": "https://finnhub.io/api/news?id=8eb2366f1687d4f584f048ddee4270fe9f7e41d7c7636c04d18e7c104927e5e0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
                "category": "company",
                "datetime": 1785333603,
                "headline": "Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates"
              },
              {
                "id": 141053250,
                "url": "https://finnhub.io/api/news?id=9e848640eda925c11e40e855bcdf8fb354486ca8917fc7e3a92131a508529c90",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q2 CY2026, with sales up 3.4% year on year to $2.74 billion. Its non-GAAP profit of $3.60 per share was 75.8% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785327345,
                "headline": "Biogen (NASDAQ:BIIB) Reports Upbeat Q2 CY2026"
              }
            ],
            "raw_source": [
              {
                "id": 141237366,
                "url": "https://finnhub.io/api/news?id=7520059c1e635c3a1db5a71abc23c482a4e538243e4691dbd434400fd30c87ea",
                "image": "https://www.chartmill.com/images/uploads/CM_Breakout_Stocks_Small_free_bb09e243c7.webp",
                "source": "ChartMill",
                "related": "BIIB",
                "summary": "Biogen (BIIB) flashes a perfect technical rating and strong breakout setup, with a proposed entry at $215.61 and defined stop.",
                "category": "company",
                "datetime": 1786965108,
                "headline": "Biogen (NASDAQ:BIIB) Shows Strong Technical Breakout Setup With Perfect Trend Rating"
              },
              {
                "id": 141206518,
                "url": "https://finnhub.io/api/news?id=9069d19d991acf04b9fca1c8a243ae50a474fe8d50a62762c1f60f1f800987d3",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Investing.com -- Wolfe Research upgraded two major pharmaceutical companies to Outperform on Thursday, citing stronger growth prospects, attractive valuations and a series of upcoming clinical catalysts.",
                "category": "company",
                "datetime": 1786629121,
                "headline": "Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation"
              },
              {
                "id": 141220042,
                "url": "https://finnhub.io/api/news?id=6126f4a3598717ae72957a00daec419da16ec28cdf3b4b54ad6be6e2ceb84f3a",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Wolfe Research  analyst Alexandria Hammond   upgrades Biogen (NASDAQ:BIIB) from Peer Perform to Outperform and announces $300 price target.",
                "category": "company",
                "datetime": 1786627086,
                "headline": "Wolfe Research Upgrades Biogen to Outperform, Announces $300 Price Target"
              },
              {
                "id": 141202392,
                "url": "https://finnhub.io/api/news?id=e4f534767d2a50f66cd7b64306d03ecb7791615e3b83878d74f2559919d43009",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Key Highlights Multi-indication precedent: Biogen’s approximately $5.6 billion acquisition of Apellis added EMPAVELI for PNH and SYFOVRE for GA, both of which contain pegcetacoplan.Primate proof of concept: A single intravitreal dose of NM5072 reduced CNV, hemorrhage, and retinal fibrosis in a rhesus monkey model.Phase I clinical experience: NM5072 completed a Phase I study in 48 healthy volunteers and received FDA Orphan Drug Designation for PNH.Potential extended durability: Rabbit PK/PD data",
                "category": "company",
                "datetime": 1786476420,
                "headline": "NovelMed Advances NM5072 for Multiple Ocular Disorders"
              },
              {
                "id": 141154813,
                "url": "https://finnhub.io/api/news?id=d1a25cbee937c8d8a8e9cf11267b548cc0e980b847cbb4c2a4d7e9ec0901a396",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Growth portfolio revenue surpassed legacy MS franchise for second consecutive quarter.",
                "category": "company",
                "datetime": 1786147363,
                "headline": "Biogen (BIIB) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141152607,
                "url": "https://finnhub.io/api/news?id=48a15f02370395e8743eb7ee8e2fba3e450d9a12cf1ce3dfbe41f0542decbd91",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Denali Therapeutics narrows Q2 loss as Avlayah sales top estimates, with strong launch traction and pipeline updates shaping its outlook.",
                "category": "company",
                "datetime": 1786127460,
                "headline": "DNLI Q2 Loss Narrows, Avlayah Sales Drive Strong Launch Momentum"
              },
              {
                "id": 141142421,
                "url": "https://finnhub.io/api/news?id=acb4e73a3041fcb7d54265b280fd14793764bcd4076464de33027ecf40a8618d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Lead program now in Phase 1 developmentCAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately held biotechnology company focused on discovering and developing small-molecule therapies in immunology. The acquisition strengthens Biogen’s growing immunology portfolio, adding multiple assets that have potential to treat immune-mediated conditions across a range of indications. The lead program ent",
                "category": "company",
                "datetime": 1786054500,
                "headline": "Biogen Completes Acquisition of RayThera Inc."
              },
              {
                "id": 141124142,
                "url": "https://finnhub.io/api/news?id=813b61ff173410e35cfda53343740d8fb9f8423f3c6efbe76794361cc15bba02",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2287921356/image_2287921356.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Stoke Therapeutics stays a Buy as zorevunersen hits key Dravet milestones and STK-002 advances; strong cash runway to 2028. Click for more on STOK stock.",
                "category": "company",
                "datetime": 1785937802,
                "headline": "Stoke: 'Buy' On Zorevunersen NDA SCN1A DS And STK-002 Advancement"
              },
              {
                "id": 141121433,
                "url": "https://finnhub.io/api/news?id=3a98143434c8171b885ecc05539ec42e9793a2eccf3c1806a206e3807551a4d0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen is one of the oldest and most venerable biotechs. For a time in the late 1990s, Biogen's share price grew ninefold.",
                "category": "company",
                "datetime": 1785931257,
                "headline": "Biogen Stock: How To Find & Own America's Greatest Opportunities"
              },
              {
                "id": 141113551,
                "url": "https://finnhub.io/api/news?id=f5cc7f1ae64aea116a271c65e82271dfde8ba061a18c8abc59aa150620b17193",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Mizuho  analyst Salim Syed   maintains Biogen (NASDAQ:BIIB) with a Outperform and raises the price target from $221 to $241.",
                "category": "company",
                "datetime": 1785852660,
                "headline": "Mizuho Maintains Outperform on Biogen, Raises Price Target to $241"
              },
              {
                "id": 139933841,
                "url": "https://finnhub.io/api/news?id=044dc24162ea80adbeadbcfeb5a727025931ea7dcde67efa283f4b30078c67c5",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "",
                "category": "company",
                "datetime": 1785847006,
                "headline": "Incyte Appoints Suketu (Suky) Upadhyay As Executive Vice President And CFO Effective May 4, 2026"
              },
              {
                "id": 141102903,
                "url": "https://finnhub.io/api/news?id=1616416f52964b33626780df4bbf688e25cb5403a3309b1f71b9e4583bd1f513",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Amgen, Pfizer, Eli Lilly, Merck and Novo Nordisk are set to report Q2 results this week after a strong start for pharma earnings. Which names could beat forecasts?",
                "category": "company",
                "datetime": 1785778200,
                "headline": "Are These 5 Pharma Stocks Set to Surpass Q2 Earnings Forecasts?"
              },
              {
                "id": 141113553,
                "url": "https://finnhub.io/api/news?id=f7c2209a9def396e33dd95f2d9d2872abc535fbadef0aeafe79b4a3bdf588e60",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Citigroup  analyst Geoff Meacham   maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $200 to $215.",
                "category": "company",
                "datetime": 1785767873,
                "headline": "Citigroup Maintains Neutral on Biogen, Raises Price Target to $215"
              },
              {
                "id": 141100761,
                "url": "https://finnhub.io/api/news?id=7b92ac9f780895129eea930a6651202fe06c8fc6ae0dee90844ddfa38d9415cc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.",
                "category": "company",
                "datetime": 1785767640,
                "headline": "4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates"
              },
              {
                "id": 141087814,
                "url": "https://finnhub.io/api/news?id=79c85db271e7d964af8764123ce35f25b0d723af71c3b68905827751789ec757",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biotech company Biogen (NASDAQ:BIIB) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 3.4% year on year to $2.74 billion. Its non-GAAP profit of $3.60 per share was 75.8% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785599277,
                "headline": "BIIB Q2 Deep Dive: Portfolio Expansion and Pipeline Readouts Drive Upbeat Outlook"
              },
              {
                "id": 141081582,
                "url": "https://finnhub.io/api/news?id=fbee925dabbe6f460ef2b4b28c54e17bf35b8224f7677ab26790e7608838499f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The biotech's shares have stumbled after a guidance change, and investors are weighing whether this is the moment to step in or step aside.",
                "category": "company",
                "datetime": 1785526149,
                "headline": "Is The Recent Pullback In Alnylam Stock An Opportunity Or A Trap?"
              },
              {
                "id": 141070848,
                "url": "https://finnhub.io/api/news?id=891e489f7895a66c6bdabdf73f2f1af2c3b647435235df64066b2c206308d815",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Ionis beats Q2 revenues and earnings estimates as commercial growth offsets tough comparisons, while reaffirming its 2026 outlook.",
                "category": "company",
                "datetime": 1785433560,
                "headline": "IONS Beats Q2 Earnings & Sales Estimates, Reiterates '26 Outlook"
              },
              {
                "id": 141079500,
                "url": "https://finnhub.io/api/news?id=f7cc43de75b589ff54cd3ec172ffea5c55862ac82812b9c6bf226cf2329f5cdd",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "UBS  analyst Michael Yee   maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $225 to $240.",
                "category": "company",
                "datetime": 1785429109,
                "headline": "UBS Maintains Buy on Biogen, Raises Price Target to $240"
              },
              {
                "id": 141070208,
                "url": "https://finnhub.io/api/news?id=d73b935868f1be90c5afd21a24440f30d18e87b322411a6f119d7215a4343536",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "HC Wainwright & Co.  analyst Andrew S. Fein   maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $237 to $251.",
                "category": "company",
                "datetime": 1785424208,
                "headline": "HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $251"
              },
              {
                "id": 141070209,
                "url": "https://finnhub.io/api/news?id=901908e305222fa30e9e6df0498c809f80e261bb0ad34d56f46e01fbbefb8753",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Morgan Stanley  analyst Matthew Harrison   maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $222 to $231.",
                "category": "company",
                "datetime": 1785417953,
                "headline": "Morgan Stanley Maintains Equal-Weight on Biogen, Raises Price Target to $231"
              },
              {
                "id": 141070210,
                "url": "https://finnhub.io/api/news?id=b44380759e05ae65208e0b6dbbba1adc3d7d3f1d8cf6459d7262c85dbd266ddb",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "RBC Capital  analyst Brian Abrahams   maintains Biogen (NASDAQ:BIIB) with a Outperform and lowers the price target from $242 to $240.",
                "category": "company",
                "datetime": 1785417745,
                "headline": "RBC Capital Maintains Outperform on Biogen, Lowers Price Target to $240"
              },
              {
                "id": 141070211,
                "url": "https://finnhub.io/api/news?id=0f088f6cf39f50aea7042a163a8e5f109458aad370cfec3ed0a722618b889a23",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Canaccord Genuity  analyst Sumant Kulkarni   maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $245 to $248.",
                "category": "company",
                "datetime": 1785411715,
                "headline": "Canaccord Genuity Maintains Buy on Biogen, Raises Price Target to $248"
              },
              {
                "id": 141070212,
                "url": "https://finnhub.io/api/news?id=a414e6454339cbb94ed5dfe671357e898c62fa92dfcf33a3370ad3652392f1d0",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "TD Cowen  analyst Phil Nadeau   maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $215 to $225.",
                "category": "company",
                "datetime": 1785411686,
                "headline": "TD Cowen Maintains Buy on Biogen, Raises Price Target to $225"
              },
              {
                "id": 141070213,
                "url": "https://finnhub.io/api/news?id=a64cdda1ea51d6f09da7ae5e53045a8db9be569b5e7f6ef480a3d9a27d372fe3",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Wedbush  analyst Laura Chico   maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $201 to $215.",
                "category": "company",
                "datetime": 1785404453,
                "headline": "Wedbush Maintains Neutral on Biogen, Raises Price Target to $215"
              },
              {
                "id": 141063522,
                "url": "https://finnhub.io/api/news?id=34ff54a8cc17094f79ad56c7f69dd8888cad6a9c08f1569e4bc5d2b14f34c7e7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Inc. has released its second-quarter 2026 results, reporting revenue of US$2.74 billion versus US$2.65 billion a year earlier, while net income dropped to US$97.5 million and diluted EPS from continuing operations fell to US$0.66 from US$4.33. Despite modest revenue growth for both the quarter and first half of 2026, Biogen’s profitability compressed sharply, with six‑month net income falling to US$417.0 million from US$875.3 million, highlighting a widening gap between sales...",
                "category": "company",
                "datetime": 1785391731,
                "headline": "Biogen (BIIB) Is Up 5.8% After Earnings Compression Amid Revenue Growth – Is Profitability Peaking?"
              },
              {
                "id": 141059663,
                "url": "https://finnhub.io/api/news?id=e878947f767b5f20331c91f468e260ff4861a905da81a14521dec058a3a731ee",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "The company published its second-quarter results on Wednesday morning.",
                "category": "company",
                "datetime": 1785368580,
                "headline": "Why Biogen Stock Topped the Market Today"
              },
              {
                "id": 141058596,
                "url": "https://finnhub.io/api/news?id=bcb4bce5f67ee0ae88d03f86cff4bcf7e28aac5f04e8b3f4a884222a40c71393",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen Inc (BIIB) reports a 3% revenue increase, driven by a robust growth portfolio and strategic acquisitions, despite facing market challenges.",
                "category": "company",
                "datetime": 1785359014,
                "headline": "Biogen Inc (BIIB) Q2 2026 Earnings Call Highlights: Strong Growth in Core Pharmaceuticals and ..."
              },
              {
                "id": 141056947,
                "url": "https://finnhub.io/api/news?id=b603a696c3ad32b26eea35e7acb3b9e37eb7f5a6acf4903dee490a13eb42463a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Moby summary of Biogen Inc.'s Q2 2026 earnings call",
                "category": "company",
                "datetime": 1785353490,
                "headline": "Biogen Inc. Q2 2026 Earnings Call Summary"
              },
              {
                "id": 141055975,
                "url": "https://finnhub.io/api/news?id=f88459dae0f7166f972d7a518413d9253735fcca2063a2c6ca5bdc1fee27b7d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Teva Pharmaceutical Industries climbed above an important chart level Wednesday, after the company's bullish guidance overshadowed mixed second-quarter results.  Teva earnings thinned to 2 cents a share after subtracting costs from an acquisition.  The profit came in below the consensus estimate of 5 cents a share.",
                "category": "company",
                "datetime": 1785345656,
                "headline": "Drugmakers Climb On Q2 Reports, Even As One Misses Profit Views"
              },
              {
                "id": 141055796,
                "url": "https://finnhub.io/api/news?id=642b6eda2a5c39263b9ab36de6e6bb1ae6e1ad94fee7e1fb4751cd9d7b9dc625",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen’s growth portfolio, which includes one closely watched Alzheimer’s drug, is a bright spot in the second quarter.",
                "category": "company",
                "datetime": 1785342060,
                "headline": "Why Biogen Stock Is Resisting a Market Downturn After Earnings"
              },
              {
                "id": 141056937,
                "url": "https://finnhub.io/api/news?id=0873deb1760e30eec26325069b9aef7c10238b0e43c98c712ebff7fe9c252aae",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Biogen Inc. (BIIB) Q2 2026 Earnings Call July 29, 2026 8:30 AM EDTCompany ParticipantsTim Power - Head of Investor RelationsChristopher Viehbacher -...",
                "category": "company",
                "datetime": 1785340401,
                "headline": "Biogen Inc. (BIIB) Q2 2026 Earnings Call Transcript"
              },
              {
                "id": 141055977,
                "url": "https://finnhub.io/api/news?id=fed3577fc8a0490e8bfa454f6857e864769160cb170f1e970b3df7f0416ac869",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen tops Q2 earnings and revenue estimates as growth drugs fuel sales, offset MS declines, and support a higher 2026 revenue and EPS outlook.",
                "category": "company",
                "datetime": 1785337740,
                "headline": "Biogen's Q2 Earnings Beat, New Drugs Drive Sales, 2026 Guidance Raised"
              },
              {
                "id": 141054425,
                "url": "https://finnhub.io/api/news?id=1a0ccbe58908a26310dec99566bfa6d8d2006cab56d23e1638b6e1b1e9ec0d57",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (NASDAQ:BIIB) reported second-quarter 2026 total revenue of $2.7 billion, up 3% from a year earlier, as growth products and the recently completed acquisition of Apellis contributed to results. Core pharmaceutical revenue rose 4% year over year to $1.8 billion, while the company’s growth port",
                "category": "company",
                "datetime": 1785333859,
                "headline": "Biogen Q2 Earnings Call Highlights"
              },
              {
                "id": 141054426,
                "url": "https://finnhub.io/api/news?id=8eb2366f1687d4f584f048ddee4270fe9f7e41d7c7636c04d18e7c104927e5e0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.",
                "category": "company",
                "datetime": 1785333603,
                "headline": "Biogen (BIIB) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates"
              },
              {
                "id": 141059866,
                "url": "https://finnhub.io/api/news?id=3a1b396f3a193bab276960903df1609cee8d23faa0ff5a2169aa11d3ea6a588a",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/29/Biogen-World-Headquarters-At-225-Binney-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Biogen beat second-quarter earnings and revenue estimates, raised its 2026 guidance, and reported pipeline progress.",
                "category": "company",
                "datetime": 1785332206,
                "headline": "Biogen Boosts Profit Forecast with Growth Across Alzheimer's, Rare Disease Portfolio"
              },
              {
                "id": 141053249,
                "url": "https://finnhub.io/api/news?id=5d800f468473e98a2c5100133b735d2060b32339332301e0be3b6672512a30d4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (NASDAQ:BIIB) reported stronger-than-expected second-quarter results on Wednesday, with revenue and adjusted earnings exceeding Wall Street forecasts as its expanding portfolio of growth products continued to offset weakness in its legacy multiple sclerosis business. The biotechnology company posted revenue of $2.",
                "category": "company",
                "datetime": 1785327401,
                "headline": "Biogen Beats Second-Quarter Expectations as Growth Portfolio Drives Revenue Higher"
              },
              {
                "id": 141053250,
                "url": "https://finnhub.io/api/news?id=9e848640eda925c11e40e855bcdf8fb354486ca8917fc7e3a92131a508529c90",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biotech company Biogen (NASDAQ:BIIB) announced better-than-expected revenue in Q2 CY2026, with sales up 3.4% year on year to $2.74 billion. Its non-GAAP profit of $3.60 per share was 75.8% above analysts’ consensus estimates.",
                "category": "company",
                "datetime": 1785327345,
                "headline": "Biogen (NASDAQ:BIIB) Reports Upbeat Q2 CY2026"
              },
              {
                "id": 141053066,
                "url": "https://finnhub.io/api/news?id=5abf50436158576a31979517d05fbd83f05d7ec4faf8fd94ceed8b0a4eaa6c1b",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen’s growth portfolio, which includes one closely watched Alzheimer’s drug, is a bright spot in the second quarter.",
                "category": "company",
                "datetime": 1785326520,
                "headline": "Why This Drugmaker’s Earnings Guidance Cut Doesn’t Tell the Full Story"
              },
              {
                "id": 141053252,
                "url": "https://finnhub.io/api/news?id=b478927a46056feeba626bbe3305da8048a1d5551702c18e7ec0f8a91ffcb9e2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) delivered earnings and revenue surprises of +18.42% and +9.40%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785324603,
                "headline": "Biogen Inc. (BIIB) Q2 Earnings and Revenues Top Estimates"
              },
              {
                "id": 141053885,
                "url": "https://finnhub.io/api/news?id=1f15877a1001ae15dd5a3cd545b026512debdef79ac455207e35e507121673e3",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2238013673/image_2238013673.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Biogen Inc. upgraded to Buy: Q2 revenue +3%, LEQEMBI traction, and felzartamab catalysts drive upside. Click for this BIIB earnings update.",
                "category": "company",
                "datetime": 1785324567,
                "headline": "Biogen: The Turnaround Is Real Enough To Buy (Rating Upgrade)"
              },
              {
                "id": 141054427,
                "url": "https://finnhub.io/api/news?id=846973aa10402577b458d69661dc5bd7cac39f8cf95aa30249bc7a697e6bbc93",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall Street that they can hit ambitious revenue targets.",
                "category": "company",
                "datetime": 1785323580,
                "headline": "Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push"
              },
              {
                "id": 141052252,
                "url": "https://finnhub.io/api/news?id=6db8a7113e7159ccb704f68f588809abf63564a3140aaf4b72b0f3becbd1eda4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Investing.com -- Biogen reported second-quarter revenue and adjusted profit above analysts’ estimates on Wednesday, helped by 24% growth in its Growth Portfolio and stronger revenue from recently acquired products, although sales of its Alzheimer’s drug Leqembi narrowly missed expectations.",
                "category": "company",
                "datetime": 1785321928,
                "headline": "Biogen Q2 revenue, adjusted EPS beat estimates as growth portfolio lifts sales"
              },
              {
                "id": 141052253,
                "url": "https://finnhub.io/api/news?id=9afab3629373368e5c62797f2b5ea2a6a51d921425c4d56407f4fbea96cd923f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of JPY 29.3 billion were recorded in the period. This results in a royalty to BioArctic amounting to SEK 179 million, which is an increase of approximately 10 percent compared to the royalty recorded by BioArctic for the second quarter 2025.",
                "category": "company",
                "datetime": 1785321000,
                "headline": "Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026"
              },
              {
                "id": 141052175,
                "url": "https://finnhub.io/api/news?id=b87a3f7d28d6995fee006d6de2c58bc3e201493a75af9c698a57fcac9470ce53",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen’s growth portfolio, which includes one closely watched Alzheimer’s drug, is a bright spot in the second quarter.",
                "category": "company",
                "datetime": 1785320940,
                "headline": "Biogen Raises Revenue Guidance as Growth Portfolio Outpaces Legacy Blockbuster Drugs"
              },
              {
                "id": 141059867,
                "url": "https://finnhub.io/api/news?id=9e65778ac7e74a8a1b29d5c5cdbfa634c6d8c3b7f8af1c640fafc222fa95a58a",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Biogen (NASDAQ:BIIB) raises FY2026 Adj EPS guidance from $15.25-$16.25 to $15.85-$16.85 vs $12.83 analyst estimate..",
                "category": "company",
                "datetime": 1785316342,
                "headline": "CORRECTION: Biogen Raises FY2026 Adj EPS Guidance from $15.25-$16.25 to $15.85-$16.85 vs $12.83 Est"
              },
              {
                "id": 141052662,
                "url": "https://finnhub.io/api/news?id=7cf6e4c88002252010d020c92bf427ffb5da1c6c29f3d2f7bdad8f3f2406a64e",
                "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "2026-07-29. The following slide deck was published by Biogen Inc.",
                "category": "company",
                "datetime": 1785315705,
                "headline": "Biogen Inc. 2026 Q2 - Results - Earnings Call Presentation"
              },
              {
                "id": 141059868,
                "url": "https://finnhub.io/api/news?id=139dcfaedd31fc5664a1a362635ac5497d3c437a712004310622e5a88b464dda",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Barclays  analyst Emily Field   maintains Biogen (NASDAQ:BIIB) with a Equal-Weight and raises the price target from $185 to $200.",
                "category": "company",
                "datetime": 1785311880,
                "headline": "Barclays Maintains Equal-Weight on Biogen, Raises Price Target to $200"
              },
              {
                "id": 141042768,
                "url": "https://finnhub.io/api/news?id=0340072648f7776869bda85db5951d8e27a9090fec1d821da354dca9741fc893",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biotech company Biogen (NASDAQ:BIIB) will be reporting results this Wednesday before market hours. Here’s what to look for.",
                "category": "company",
                "datetime": 1785246062,
                "headline": "Biogen (BIIB) Reports Q2: Everything You Need To Know Ahead Of Earnings"
              },
              {
                "id": 141041720,
                "url": "https://finnhub.io/api/news?id=4340760a7e45a140e669280168a7ec7a122e4f7bb43f8b9c7ee0b3f947ca31d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "HRMY, ACAD, BIIB, INSM and AGIO are set to report Q2 results, with positive Earnings ESPs suggesting potential earnings surprises.",
                "category": "company",
                "datetime": 1785229080,
                "headline": "The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals"
              },
              {
                "id": 141035128,
                "url": "https://finnhub.io/api/news?id=b58d464b27d7f23f9a829bbedeecdcfeaa6027ba0087c79c62c1a13671ff8765",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Harmony Biosciences, Acadia, Biogen, Insmed and Agios show positive Earnings ESPs ahead of Q2 results, setting up closely watched earnings reports.",
                "category": "company",
                "datetime": 1785170160,
                "headline": "Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?"
              },
              {
                "id": 141036510,
                "url": "https://finnhub.io/api/news?id=2f62a044959d35ec044e5dd29682f89b92d8b07064ef346a4b280cee421af697",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2150679757/image_2150679757.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Design Therapeutics' DT-216P2 showed 6.4-point mFARS gains in Friedreich’s ataxia, but data is early. Click here to read the latest analysis on DSGN stock.",
                "category": "company",
                "datetime": 1785169866,
                "headline": "A Deeper Dive Into Design Therapeutics"
              },
              {
                "id": 141007897,
                "url": "https://finnhub.io/api/news?id=0bbfb641eb9799606d45569051d0eff09b47cebdacb86a61c292ffbb1e342cfe",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "BIIB heads into Q2 results with new launches expected to offset weaker MS drug sales as investors watch Leqembi trends and the Apellis deal impact.",
                "category": "company",
                "datetime": 1784905020,
                "headline": "Biogen Q2 Earnings: Can New Drugs Counter Falling MS Sales?"
              },
              {
                "id": 140994984,
                "url": "https://finnhub.io/api/news?id=8f14a0b5b1108d73e7c2e51a39cd5ce106eb77cf45b56fc1f41202eec13050d1",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "PTC Therapeutics (PTCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1784815229,
                "headline": "Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know"
              },
              {
                "id": 140983335,
                "url": "https://finnhub.io/api/news?id=01fd7e79a66bf3e187e0e19193f967093ecf3293cf0691383240a4c4a9bf7bec",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
                "category": "company",
                "datetime": 1784728822,
                "headline": "Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for"
              },
              {
                "id": 140978801,
                "url": "https://finnhub.io/api/news?id=31950cdc680aaed03c87b13cd3cc791d4998f3781cee034e435a3218c2641737",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/511995022/image_511995022.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "BIIB",
                "summary": "Biogen’s (BIIB) FDA-approved injectable Leqembi cuts infusion costs but risks brain bleeds; see how diranersen compares and why neither may boost valuation.",
                "category": "company",
                "datetime": 1784677610,
                "headline": "Biogen And The Limitation Of The Tau Approach To Alzheimer's Disease"
              },
              {
                "id": 140970681,
                "url": "https://finnhub.io/api/news?id=5fd866ee8c6005a3bf2bce88f2207d39cf7b4ae098a282a1c16b59bc648a03f4",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "BIIB",
                "summary": "Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.",
                "category": "company",
                "datetime": 1784637986,
                "headline": "3 Profitable Stocks We Steer Clear Of"
              },
              {
                "id": 140977482,
                "url": "https://finnhub.io/api/news?id=64f9c13c86306fd6c2b32735dbdfed93f5355ffbcb04efe640e8ece4dc41e5f4",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "Guggenheim  analyst Brad Canino   maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $260 to $280.",
                "category": "company",
                "datetime": 1784627315,
                "headline": "Guggenheim Maintains Buy on Biogen, Raises Price Target to $280"
              },
              {
                "id": 140977483,
                "url": "https://finnhub.io/api/news?id=50ab814353c7a88ebe2a3e822ce2e437a28bce905e2132afad430896dc91d5db",
                "image": "",
                "source": "Benzinga",
                "related": "BIIB",
                "summary": "B of A Securities  analyst Jason Zemansky   maintains Biogen (NASDAQ:BIIB) with a Neutral and lowers the price target from $217 to $215.",
                "category": "company",
                "datetime": 1784622854,
                "headline": "B of A Securities Maintains Neutral on Biogen, Lowers Price Target to $215"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 8,
            "negative_hits": 0,
            "positive_hits": 4,
            "recomputed_at_score": true,
            "sentiment_score_raw": 1.2,
            "source_article_count": 58,
            "discarded_article_count": 47
          },
          "sentimentPoints": 6
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 25.4,
        "grade": "優秀",
        "items": {
          "bbPoints": 3,
          "adxPoints": 3,
          "sarPoints": 2.4000000000000004,
          "vcpPoints": 3,
          "macdPoints": 4,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 3,
            "vcp_reason": "波幅收縮(16.9%→9.9%)；量縮(v10/v30=0.65)；跌縮量(近10日4日)；站上MA50；Ready=Y；Confirm=N",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 1195866.6666666667,
              "down_days": 4,
              "vcp_ready": true,
              "above_ma50": true,
              "avg_vol_10": 777770,
              "avg_vol_20": 968780,
              "avg_vol_30": 1195866.6666666667,
              "range_pct_10": 0.09867034762442979,
              "range_pct_20": 0.11770463644951551,
              "range_pct_30": 0.16850939731703302,
              "up_expand_ok": false,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": true,
              "down_shrink_ok": true,
              "up_expand_days": 0,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.6503818708886163,
              "dist_to_20d_high": 0.03511132275990651,
              "down_shrink_days": 4,
              "breakout_level_20d": 222.14999,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.585548041803222
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": true
          },
          "kdjAdxPoints": 0.8,
          "rsiKdjPoints": 4,
          "volumeWeight": 2,
          "maCrossPoints": 2.4,
          "shortRsiPoints": 1,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.8
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.4,
            "details": {
              "atrPct": 2.7241892827530076,
              "turnoverUsdM": 173.31462973559002,
              "liquidityPoints": 0.4,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.8,
          "stopLevels": {
            "symbol": "US.BIIB",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 202.6714,
            "strength_details": {
              "ma_score": 2,
              "atr_score": 2,
              "rsi_score": 3,
              "macd_score": 3,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1.7,
            "stop_loss_percent": 5.4,
            "take_profit_price": 233.6197,
            "target_multiplier": 2.2,
            "technical_strength": 2.25,
            "take_profit_percent": 9
          },
          "positionPoints": 1.4,
          "stopLossPoints": 1.8,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Health Care",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.6518675954309592,
          "stopLossPercent": 5.448378565506015,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.BIIB",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 5.8393,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.72
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": 164.27
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "派發",
      "score": 2,
      "value": -0.0386
    },
    "kdj": {
      "d": 66.1,
      "j": 82.18,
      "k": 71.46,
      "rule": "Cursor_18.24 K/D cross",
      "score": 6,
      "signal": "強金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "平衡",
      "score": 6,
      "value": 59.32
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 4,
      "trend": "弱勢",
      "value": -2818659,
      "recentSlope": -39335.9,
      "previousSlope": 85320
    },
    "rsi": 63.1,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 8,
      "trend": "上升",
      "value": 201.423,
      "position": "SAR喺價下",
      "distancePct": 6.03,
      "previousTrend": "上升"
    },
    "ma50": 204.8222,
    "macd": {
      "macd": 3.010442926657788,
      "trend": "強烈看漲",
      "signal": 1.9994684448837128,
      "histogram": 1.0109744817740753
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 10,
      "value": 207.8765,
      "position": "連續5日>VWAP",
      "consecutiveAbove": 7
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "無力",
      "ratio": 0.84,
      "score": 4,
      "avgVolume": 957603,
      "currentVolume": 808559
    },
    "derived": {
      "ma20": 207.8575,
      "ma50": 204.8222,
      "prevClose": 221.56,
      "avgVolume10": 769366,
      "avgVolume20": 957603,
      "changePercent": -3.25,
      "avgVolumeForScore": 957603
    },
    "ma_cross": {
      "ma20": 207.8575,
      "ma50": 204.8222,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "接近",
      "score": 6,
      "prevMa20": 207.171,
      "prevMa50": 204.5172,
      "spreadPct": 1.48,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 198.4119,
      "upper": 217.3031,
      "position": "上半部"
    },
    "rsi_short": 61.97,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.84
    }
  }
}

{
  "close": 214.35,
  "volume": 808559,
  "changePercent": -3.25
}